Intelligence · Patent portfolio
Compass Therapeutics Patents
Full USPTO pharma patent portfolio for Compass Therapeutics — grant dates, expiration, and drug cross-links.
- Patents
- 100
- Expiring ≤24m
- 0
Quick answer
Compass Therapeutics has 100 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
-
US 8580748
Peptides for the treatment of hearing
granted -
US 8535260
Devices, systems, and methods for localized drug delivery
granted -
US 8450285
Immunoregulatory peptides and methods of use
granted -
US 6994994
Splice variants of CD40-receptor
expired
Frequently asked questions
How many patents does Compass Therapeutics have?
100 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Compass Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory